Salem, Mass. – May 21, 2021 – Over the past 10 years, Commonwealth Diagnostics International, Inc. (CDI) leadership team has worked closely with industry stakeholders to support the gastroenterology (GI) community. Today, CDI is pleased to announce it has expanded partnerships with several industry and research partners both in the United States and abroad, including the American College of Gastroenterology (ACG), Owlstone Medical, and the Rome Foundation.
ACG partnership with MyGiHealth
CDI and its MyGiHealth platform have partnered with ACG to provide patients with access to the most current research and information on digestive distress and functional GI ailments. Designed by industry-leading GI physicians, MyGiHealth is a cloud-based, patient-focused healthcare application that enables patients to monitor, manage, and understand their symptoms while enhancing the patients’ relationship and communication with their integrated care team.
Through the new partnership, ACG will provide enhanced educational tools and content that will better support patients in their ability to identify and track symptoms as well as find GI providers in their geographic area via an enhanced physician lookup tool. The new tools and content are available on the MyGiHealth website and downloadable IOS app.
Owlstone Medical partnership with Functional Gut Diagnostics
CDI and its U.K. joint venture, Functional Gut Diagnostics (FGD), have entered into a Lab Services Agreement and Collaboration Agreement with Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine. FGD is a 50/50 joint venture between CDI and Dr. Anthony Hobson and his Functional Gut Clinic in the U.K.
The Lab Services Agreement will help further advance CDI’s mission to help healthcare providers worldwide identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. Under the terms of the agreements, Owlstone and FGD will be distributing CDI’s ISO13485-certified, CE marked at-home breath test kits for small intestinal bacterial overgrowth (SIBO) and carbohydrate malabsorption disorders in the UK.
Additionally, the Collaboration Agreement will further CDI’s endeavor to create a more personalized and precision-based approach to functional GI diagnostics through the development and validation of new, novel diagnostic test solutions. Tests developed under the Agreement will be made available to patients in the U.K. through FGD and patients in the U.S. through CDI.
CDI extends Rome Foundation sponsorship
CDI is pleased to announce its continued sponsorship and support of the Rome Foundation, whose mission is to improve the lives of people with Disorders of Brain-Gut Interaction (formerly Functional GI Disorders). As part of its ongoing sponsorship, CDI continues to work with Rome Foundation to bring the latest information and research to the GI community. Last month, CDI sponsored two Rome Foundation and World IBS Day webinars geared to patients and providers on the myths and misconceptions of Irritable Bowel Syndrome. And with Digestive Disease Week® (DDW®) being a virtual event for the second year in a row, CDI will host a Post-DDW Functional GI Trends webinar event on May 27th. This event will break down the newest trends, hottest topics and important research discussed during the 3-day event and is endorsed by the Rome Foundation.
Craig Strasnick, president and CEO of CDI, commented: “As a trusted partner for functional GI diagnostics, our team strives to find opportunities to build relationships with industry partners who are aligned with our mission to bring products to market that are meaningful and helpful to both healthcare providers and patients worldwide. These new and expanded relationships will lead to greater awareness and education, better diagnostic and treatment pathways, and improved patient outcomes.”
About Commonwealth Diagnostics International, Inc. (CDI):
Commonwealth Diagnostics International, Inc. (CDI) is an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. Focused on our patient-centric principles, our cost-effective portfolio of diagnostic products results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Our expansive portfolio includes non-invasive at-home breath testing kits for Small Intestinal Bacterial Overgrowth (SIBO), Intestinal Methane Overgrowth (IMO), and carbohydrate malabsorption disorders, as well as IBSchek®, a proprietary capillary collection test for Irritable Bowel Syndrome (IBS-D/M), and MyGIHealth, a cloud-based platform that enables patients to monitor, manage and understand their GI-related symptoms. Operating out of our CLIA-certified laboratory, and as an FDA registered, ISO 13485 certified medical device manufacturer, we pride ourselves on our partnerships with industry-leading health systems, hospitals, and private practices worldwide. For more information, visit commdx.com.
